A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma
Study Details
Study Description
Brief Summary
An open-label multi-center phase Ib/II study to evaluate the efficacy and safety of anti-PD-1/CTLA-4 bispecific antibody AK104 plus lenvatinib as the first-line therapy for patients with advanced hepatocellular carcinoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
This is a multi-center, multi-cohort, open-label phase 1b/2 clinical study to evaluate the anti-tumor activity, safety, PK profile, immunogenicity and potential biomarkers of AK104 plus lenvatinib for the treatment of advanced hepatocellular carcinoma.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: AK104 and Lenvatinib AK104 6 mg/kg IV every 2 weeks (Q2W) Lenvatinib 12mg weight≥60kg or 8mg weight<60kg,PO QD |
Biological: AK104
Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
Drug: Lenvatinib
Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
|
Outcome Measures
Primary Outcome Measures
- Objective response rate (ORR) [Up to 2 years]
ORR is defined as the proportion of subjects with confirmed CR or PR, based on RECIST v1.1.
Secondary Outcome Measures
- Disease control rate (DCR) [Up to 2 years]
The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD for ≥8 weeks) based on RECIST Version 1.1.
- Duration of response (DoR) [Up to 2 years]
Duration of response is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first
- Progression-free survival (PFS) [Up to 2 years]
Progression-free survival is defined as the time from the start of treatment with AK104 until the first documentation of disease progression or death due to any cause, whichever occurs first.
- Number of participants with adverse events (AEs) [the time of informed consent signed through 90 days after the last dose of AK104 and]
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.
- Observed concentrations of AK104 [From first dose of AK104 through 90 days after last dose of AK104]
The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration.
- Number of subjects who develop detectable anti-drug antibodies (ADAs) [From first dose of AK104 through 90 days after last dose of AK104]
The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed written informed consent form voluntarily.
-
Histologically or cytologically documented hepatocellular carcinoma.
-
BCLC stage C, and non-resectable BCLC stage B .
-
At least one measurable lesion according to RECIST criteria.
-
ECOG of 0 or 1.
-
Adequate organ function.
-
Estimated life expectancy of ≥3 months.
-
For women of childbearing potential: agreement to remain abstinent; For men: agreement to remain abstinent.
Exclusion Criteria:
-
Histologically or cytologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, cholangiocarcinoma, etc.
-
History of hepatic encephalopathy or liver transplantation.
-
Clinical significance of hydrothorax, ascites or pericardial effusion.
-
Central nervous system metastases and/or carcinomatous meningitis.
-
Any risk of bleeding; severe bleeding tendency or coagulation dysfunction, or under thrombolytic therapy.
-
Occurred arteriovenous thromboembolic events within 6 months before the first administration.
-
Tumor volume > 50% liver volume; portal vein tumor thrombus or inferior vena cava tumor thrombus.
-
Inadequately controlled arterial hypertension.
-
Attack of symptomatic congestive heart failure (LVEF<50%); History of congenital long QT syndrome.
-
Known presence or history of interstitial lung disease or required hormone treatment interstitial lung disease.
-
Severe infections.
-
Receipt of any anti-tumor treatment, chemotherapy, targeted therapy, immunotherapy,
-
Enrollment of another clinical study within 4 weeks prior to the first administration of study drugs.
-
Unable to receive an enhanced CT or MRI scan of the liver.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Chinese PLA General Hospital | Beijing | Beijing | China |
Sponsors and Collaborators
- Akeso
- Akeso Pharmaceuticals, Inc.
Investigators
- Principal Investigator: Li Bai, MD, Chinese PLA General Hospital
- Principal Investigator: Shunchang Jiao, MD, Chinese PLA General Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AK104-206